Cargando…
High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study
BACKGROUND: Patients <60 years old with high-risk diffuse large B-cell lymphoma (DLBCL) receiving standard RCHOP(E) treatment display high relapse rates. Here, we compared this standard regimen to a high-intensity regimen in terms of recurrence and long-term survival. MATERIAL/METHODS: Newly diag...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913830/ https://www.ncbi.nlm.nih.gov/pubmed/27232105 http://dx.doi.org/10.12659/MSM.895383 |
_version_ | 1782438466088337408 |
---|---|
author | Ma, Xiaorong Xu, Yan Zhang, Wanggang Wang, Jin Cao, Xingmei Chen, Yinxia He, Aili Liu, Jie Wang, Jianli Zhao, Wanhong Yang, Yun |
author_facet | Ma, Xiaorong Xu, Yan Zhang, Wanggang Wang, Jin Cao, Xingmei Chen, Yinxia He, Aili Liu, Jie Wang, Jianli Zhao, Wanhong Yang, Yun |
author_sort | Ma, Xiaorong |
collection | PubMed |
description | BACKGROUND: Patients <60 years old with high-risk diffuse large B-cell lymphoma (DLBCL) receiving standard RCHOP(E) treatment display high relapse rates. Here, we compared this standard regimen to a high-intensity regimen in terms of recurrence and long-term survival. MATERIAL/METHODS: Newly diagnosed DLBCL patients <60 years old who were treated at the Second Hospital Affiliated with Xi’an Jiaotong University between January 2004 and December 2013 (n=198, 18–60 years) were included in the study. The high-intensity group included 107 patients (54.0%) who received >8 courses of chemotherapy (high-dose CHOP, CHOP-E, EPOCH, MAED, MMED, and HyperCVAD). The control group included 91 patients (46.0%) who received 6–8 courses of CHOP-based treatment. Response rate (RR), survival, relapse, and adverse effects were compared. RESULTS: Baseline characteristics of the patients were similar between the 2 groups. Median follow-up was 64.5 months. RR in the high-intensity and control groups was 88.8% and 84.6% (P=0.387), respectively; 5-year overall survival was 66.4% and 36.3% (P<0.001), respectively; 5-year progression-free survival was 56.1% and 28.6% (P<0.001), respectively; 5-year disease-free survival was 54.2% and 24.2% (P<0.001), respectively; and relapse rate during follow-up was 29.5% and 67.5% (P<0.001), respectively. There were no significant differences in adverse effects between the 2 groups. CONCLUSIONS: High-intensity chemotherapy is associated with better prognosis of patients <60 years old with newly diagnosed high-risk DLBCL. |
format | Online Article Text |
id | pubmed-4913830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-49138302016-06-28 High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study Ma, Xiaorong Xu, Yan Zhang, Wanggang Wang, Jin Cao, Xingmei Chen, Yinxia He, Aili Liu, Jie Wang, Jianli Zhao, Wanhong Yang, Yun Med Sci Monit Clinical Research BACKGROUND: Patients <60 years old with high-risk diffuse large B-cell lymphoma (DLBCL) receiving standard RCHOP(E) treatment display high relapse rates. Here, we compared this standard regimen to a high-intensity regimen in terms of recurrence and long-term survival. MATERIAL/METHODS: Newly diagnosed DLBCL patients <60 years old who were treated at the Second Hospital Affiliated with Xi’an Jiaotong University between January 2004 and December 2013 (n=198, 18–60 years) were included in the study. The high-intensity group included 107 patients (54.0%) who received >8 courses of chemotherapy (high-dose CHOP, CHOP-E, EPOCH, MAED, MMED, and HyperCVAD). The control group included 91 patients (46.0%) who received 6–8 courses of CHOP-based treatment. Response rate (RR), survival, relapse, and adverse effects were compared. RESULTS: Baseline characteristics of the patients were similar between the 2 groups. Median follow-up was 64.5 months. RR in the high-intensity and control groups was 88.8% and 84.6% (P=0.387), respectively; 5-year overall survival was 66.4% and 36.3% (P<0.001), respectively; 5-year progression-free survival was 56.1% and 28.6% (P<0.001), respectively; 5-year disease-free survival was 54.2% and 24.2% (P<0.001), respectively; and relapse rate during follow-up was 29.5% and 67.5% (P<0.001), respectively. There were no significant differences in adverse effects between the 2 groups. CONCLUSIONS: High-intensity chemotherapy is associated with better prognosis of patients <60 years old with newly diagnosed high-risk DLBCL. International Scientific Literature, Inc. 2016-05-27 /pmc/articles/PMC4913830/ /pubmed/27232105 http://dx.doi.org/10.12659/MSM.895383 Text en © Med Sci Monit, 2016 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) |
spellingShingle | Clinical Research Ma, Xiaorong Xu, Yan Zhang, Wanggang Wang, Jin Cao, Xingmei Chen, Yinxia He, Aili Liu, Jie Wang, Jianli Zhao, Wanhong Yang, Yun High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study |
title | High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study |
title_full | High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study |
title_fullStr | High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study |
title_full_unstemmed | High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study |
title_short | High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study |
title_sort | high-intensity chemotherapy is associated with better prognosis in young patients with high-risk diffuse large b-cell lymphoma: a 10-year single-center retrospective cohort study |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913830/ https://www.ncbi.nlm.nih.gov/pubmed/27232105 http://dx.doi.org/10.12659/MSM.895383 |
work_keys_str_mv | AT maxiaorong highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy AT xuyan highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy AT zhangwanggang highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy AT wangjin highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy AT caoxingmei highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy AT chenyinxia highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy AT heaili highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy AT liujie highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy AT wangjianli highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy AT zhaowanhong highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy AT yangyun highintensitychemotherapyisassociatedwithbetterprognosisinyoungpatientswithhighriskdiffuselargebcelllymphomaa10yearsinglecenterretrospectivecohortstudy |